These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Post-injection delirium/sedation syndrome in patients treated with olanzapine pamoate: mechanism, incidence, and management. Luedecke D; Schöttle D; Karow A; Lambert M; Naber D CNS Drugs; 2015 Jan; 29(1):41-6. PubMed ID: 25424243 [TBL] [Abstract][Full Text] [Related]
9. Postinjection delirium/sedation syndrome in a transgender man undergoing hormone therapy. Gerving J; Walser H; Kelly AC Ment Health Clin; 2022 Aug; 12(4):263-266. PubMed ID: 36071735 [TBL] [Abstract][Full Text] [Related]
10. Baseline characteristics and hospitalizations in patients with schizophrenia receiving olanzapine long-acting injection: an interim analysis from a non-interventional, prospective observational safety study. Jones ME; Andrews JS; Faries DE; Landry J; Xu J; Detke HC; Chhabra-Khanna R; McDonnell DP BMC Psychiatry; 2015 Nov; 15():278. PubMed ID: 26567159 [TBL] [Abstract][Full Text] [Related]
11. Case series profile of olanzapine post-injection delirium/sedation syndrome. Seebaluck J; Downes MA; Brown J; Harris K; Isoardi KZ; Chan BS Br J Clin Pharmacol; 2023 Feb; 89(2):903-907. PubMed ID: 36349832 [TBL] [Abstract][Full Text] [Related]
12. Olanzapine pamoate for the treatment of schizophrenia. Naber D Expert Opin Pharmacother; 2011 Mar; 12(4):627-33. PubMed ID: 21254860 [TBL] [Abstract][Full Text] [Related]
13. Olanzapine pamoate for the treatment of schizophrenia--a safety evaluation. Samalin L; Garay R; Ameg A; Llorca PM Expert Opin Drug Saf; 2016; 15(3):403-11. PubMed ID: 26761429 [TBL] [Abstract][Full Text] [Related]
14. A 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendation. Anand E; Berggren L; Deix C; Tóth Á; McDonnell DP Neuropsychiatr Dis Treat; 2015; 11():1349-57. PubMed ID: 26064053 [TBL] [Abstract][Full Text] [Related]
15. Olanzapine pamoate: a stick in time? A review of the efficacy and safety profile of a new depot formulation of a second-generation antipsychotic. Citrome L Int J Clin Pract; 2009 Jan; 63(1):140-50. PubMed ID: 18834452 [TBL] [Abstract][Full Text] [Related]
16. Post-Injection Delirium/Sedation Syndrome: A Case Report and 2-Year Follow-Up. Podgorná G; Albrecht J; Buday J; Mareš T; Le TH; Kališová L; Anders M Am J Case Rep; 2022 Oct; 23():e937579. PubMed ID: 36245104 [TBL] [Abstract][Full Text] [Related]
17. [Cost-effectiveness study of olanzapine pamoate: Mirror-image analysis after one year]. Potaufeu J; Langrée B; Drapier D; Burgot G; Marie N Encephale; 2019 Jun; 45(3):232-238. PubMed ID: 30579574 [TBL] [Abstract][Full Text] [Related]
18. Adverse effects associated with second-generation antipsychotic long-acting injection treatment: a comprehensive systematic review. Gentile S Pharmacotherapy; 2013 Oct; 33(10):1087-106. PubMed ID: 23776129 [TBL] [Abstract][Full Text] [Related]
19. Olanzapine Pamoate Use for Schizophrenia: Retrospective Records Based Study from a Tertiary Care Hospital. Grover S; Singla H; Chakrabarti S; Avasthi A Indian J Psychol Med; 2020; 42(2):162-167. PubMed ID: 32346258 [TBL] [Abstract][Full Text] [Related]
20. Olanzapine: a review of rapid and long-acting parenteral formulations. Owen RT Drugs Today (Barc); 2010 Mar; 46(3):173-81. PubMed ID: 20467591 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]